People with digestive issues, from leaky gut to ulcers, have reported significant improvements
8-12 hours IM) Preferred by 64% of patients who've tried both Intramuscular (into deltoid or vastus lateralis, using a 22-25 gauge, 1-inch needle): 41% report injection-site soreness Faster absorption More difficult self-administration for some sites (deltoid requires non-dominant arm injection) Preferred by 36% of patients who've tried both The efficacy difference is minimal
Our team views BPC 157 as a more localized agent, excellent for targeting specific connective tissue injuries
MHRA Threat to clinics In communication with the MHRA, they also stated: However, we do have concerns about the level of clinical oversight present in IV vitamin therapy and injection services in general and the appropriacy of such services is currently under review. This review, if deciding on stopping treatment of B12 injections by clinics who do comply with the ridiculous rules of the MHRA, would not only negatively impact the companies and individuals who give B12 injections, but also to the people who rely on them to keep functioning both physically and mentally
The preclinical data is promising, but individual human responses vary dramatically